CapsoVision expects AI-assisted reading clearance around midyear, with CapsoCam Colon Gen 2 imaging and AI module targeted for Q3 2026
View original at seekingalpha.com“We ended the quarter with $17.9 million in cash and cash equivalents”
Lo que extrajimos de esta fuente
The claims Via News extracted from this document. We point to the source; we don't replace it.
Tariffs impacting cost of goods sold were the primary driver of gross margin decline from 54% to 48% year-over-year
60% confidenceColon study investment will continue through Q3 2026 and OpEx will only begin to trail off in Q4 2026
60% confidenceCapsoVision shipped 6,229 CapsoCam Plus capsules in Q1 2026 versus 6,447 in Q1 2025, a 3% year-over-year decrease reflecting timing of shipments moved into Q2
60% confidenceCapsoCam Colon Gen 2 development program remains on track with imaging of the second-generation capsule and AI module expected in Q3 2026
60% confidenceThe modest decrease in capsule volume was offset by a slight increase in average selling price
60% confidenceCapsoVision secured key renewals for large GI networks including Indiana University Health Systems, Providence Health Systems and Gastro Health during Q1 2026
60% confidenceIncreased OpEx driven by development work for next-generation imaging sensor under Canon agreement and CapsoCam Colon Gen 2 clinical trial activities
60% confidenceThe underlying business remains strong
60% confidenceUnderlying procedure volume reflecting end user consumption continued to expand
60% confidenceEnrollment began in the clinical study for the CapsoCam UGI/pancreatic initiative
60% confidenceRevenue and new account additions remained stable year-over-year while CapsoCams were expanded to detect a widening range of mobile diseases
60% confidenceCapsoVision is working towards a unified injectable capsule platform capable of screening for esophageal, gastric, pancreatic, liver, and colorectal cancers through a single noninvasive procedure enabled by advanced imaging and AI
60% confidenceCapsoVision ended Q1 2026 with $17.9 million in cash and cash equivalents
60% confidenceAnnual R&D spending in 2026 will be similar to 2025 as the Colon study continues through Q3
60% confidenceCapsoVision previously submitted its 510(k) application for AI-assisted reading capability for CapsoCam Plus and continues to expect clearance around midyear with commercial launch shortly thereafter
60% confidenceQ1 2026 total revenue was $2.8 million, consistent with the prior year period
60% confidenceThere was no price increase on CapsoCam Plus; the ASP increase was driven by timing and a mix shift to higher-priced international regions
60% confidenceQ1 2026 gross margin was 48% compared to 54% in Q1 2025, with the change primarily driven by tariffs impacting cost of goods sold
60% confidenceCapsoVision plans to enroll 140 patients (to ensure 120 evaluable subjects) in the pancreatic study, with 120 healthy reference subjects sourced from cloud storage; enrollment timeline cannot be speculated
60% confidenceQ1 2026 gross profit was $1.3 million with a gross margin of 48%; operating expenses were $8.4 million, up $1.5 million year-over-year
60% confidenceQ2 2026 revenue is expected to be higher than Q1 2026, and H2 2026 revenue is expected to be higher than H1 2026, driven by the anticipated launch of the AI module for CapsoCam Plus
60% confidenceIn March 2026 CapsoVision closed a $14 million private placement with participation from both new and existing investors
60% confidenceFDA meeting is expected within the next few weeks; no show stoppers to CEO's knowledge on the AI-assisted reading 510(k) application
60% confidence